MS4A1 and B-cell chronic lymphocytic leukemia: Notably, the CD3-CD20 T cell engager epcoritamab is being tested in combination with venetoclax in a prospective phase I/II trial involving patients with relapsed/refractory CLL or SLL [118,119].